Becton Dickinson is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories and the industry. The Company provides innovative solutions that help advance cellular studies and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. Becton Dickinson partners with organizations around the world to address some of the most challenging global health issues.
Type
Public
HQ
Franklin Lakes, US
Founded
1897
Size (employees)
41,933 (est)-17%
Website
bd.com
Becton Dickinson was founded in 1897 and is headquartered in Franklin Lakes, US
Report incorrect company information

Key People/Management at Becton Dickinson

Vincent Forlenza

Vincent Forlenza

Chairman of the Board, Chief Executive Officer and President
Gary Cohen

Gary Cohen

Executive Vice President and President, Global Health
James Lim

James Lim

Executive Vice President and President, Greater Asia
Christopher Reidy

Christopher Reidy

Executive Vice President, Chief Financial Officer and Chief Administrative Officer

Becton Dickinson Office Locations

Becton Dickinson has offices in Four Oaks, Franklin, St Paul, Zachary and in 93 other locations
Franklin Lakes, US (HQ)
Howe Buidling 1 Becton Dr
San Jose, US
2150 Commerce Dr
Show all (98)
Report incorrect company information

Becton Dickinson Financials and Metrics

Becton Dickinson Financials

Becton Dickinson's revenue was reported to be $12.09 b in FY, 2017
USD

Revenue (Q2, 2018)

7.3 b

Gross profit (Q2, 2018)

3.2 b

Gross profit margin (Q2, 2018), %

43.2%

Net income (Q2, 2018)

(148 m)

EBIT (Q2, 2018)

413 m

Market capitalization (22-Jun-2018)

63.5 b

Closing share price (22-Jun-2018)

237.6

Cash (31-Mar-2018)

1.3 b

EV

84.8 b
Becton Dickinson's current market capitalization is $63.5 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

8.1 b8.4 b10.3 b12.5 b12.1 b

Revenue growth, %

5%22%21%

Cost of goods sold

3.9 b4.1 b5.6 b6.5 b6.2 b

Gross profit

4.2 b4.3 b4.7 b6 b5.9 b
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018

Revenue

2 b2.1 b2.2 b2.1 b2.1 b3.1 b3 b3.1 b3.2 b2.9 b3 b3 b7.3 b

Cost of goods sold

980 m1 b1 b1 b1 b1.9 b1.6 b1.6 b1.7 b1.5 b1.5 b1.5 b4.1 b

Gross profit

1 b1.1 b1.1 b1 b1 b1.2 b1.4 b1.5 b1.5 b1.5 b1.4 b1.5 b3.2 b

Gross profit Margin, %

51%51%52%51%51%38%47%48%48%50%48%50%43%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

1.9 b1.9 b1.4 b1.5 b14.2 b

Accounts Receivable

1.2 b1.2 b1.6 b(128 m)(93 m)

Inventories

1.4 b1.5 b2 b1.7 b1.8 b

Current Assets

5.9 b6.1 b6 b6.4 b18.6 b
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018

Cash

1.7 b1.7 b1.7 b8.5 b1.9 b1.6 b1.6 b1.7 b1.7 b919 m548 m13.9 b1.3 b

Accounts Receivable

1.1 b1.1 b1.2 b1 b1.6 b1.6 b1.5 b1.6 b1.6 b1.5 b1.6 b1.7 b2.3 b

Inventories

1.5 b1.5 b1.6 b1.5 b2.3 b2 b2 b1.8 b1.8 b1.7 b1.7 b1.8 b2.5 b

Current Assets

5.7 b5.9 b6 b12.1 b7 b6.3 b5.6 b6.6 b6.5 b5.2 b4.9 b18.2 b7.5 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

1.3 b1.2 b695 m976 m1.1 b

Depreciation and Amortization

1.1 b

Inventories

(145 m)(189 m)200 m69 m(46 m)

Accounts Payable

797 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q2, 2018

Net Income

271 m287 m326 m236 m216 m(148 m)

Depreciation and Amortization

844 m

Cash From Operating Activities

1 b

Cash From Investing Activities

(15.5 b)
USDY, 2018

EV/EBIT

205.4 x

EV/CFO

83.4 x

EV/FCF

135.5 x

Financial Leverage

2.6 x
Show all financial metrics

Becton Dickinson Operating Metrics

FY, 2016

Countries

50

Facilities

255
Show all operating metrics

Becton Dickinson Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Sirigen Inc August 27, 2012
Carmel Pharma Inc July 11, 2011
Accuri Cytometers March 11, 2011
HandyLab Inc November 20, 2009$275 m
Cytopeia August 23, 2008
GeneOhm Sciences January 10, 2006
Atto Bioscience July 01, 2004$25 m
Difco June 02, 1997
Plasso Technology Limited
PreAnalytiX

Becton Dickinson Revenue Breakdown

Embed Graph

Becton Dickinson revenue breakdown by business segment: 30.7% from Life Sciences and 69.3% from Medical

Report incorrect company information

Becton Dickinson Online and Social Media Presence

Embed Graph
Report incorrect company information